2016


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2016/№3

Блокада минералокортикоидных рецепторов при лечении больных с сердечно-сосудистыми заболеваниями: клинические и фармакологические аспекты применения эплеренона

Гиляревский С. Р.1, Голшмид М. В.1, Кузьмина ;И. М.2
1 – ГБОУ ДПО «РМАПО» МЗ РФ, 123995, Москва, ул. Баррикадная, д. 2 / 1
2 – НИИ «Скорой помощи» им. Н. В. Склифосовского, 129090, Москва, Б. Сухаревская пл., д. 3

Ключевые слова: лечение, сердечно-сосудистые заболевания

DOI: 10.18087/rhj.2016.3.2198

В статье рассматриваются современные аспекты клинического применения селективного антагониста минералокортикоидных рецепторов эплеренона при лечении больных ССЗ. Приводится доказательная база применения эплеренона при лечении больных с разными заболеваниями. Обсуждаются подходы к обеспечению безопасности и переносимости препаратов, относящихся к антагонистам минералокортикоидных рецепторов.
  1. Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag. 2013;9:321–31.
  2. Funder JW. Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology. 2010 Nov;151 (11):5098–102.
  3. Deinum J, Riksen NP, Lenders JW. Pharmacological treatment of aldosterone excess. Pharmacol Ther. 2015 Oct;154:120–33.
  4. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal. 2007 Nov 30;5: e012.
  5. Funder JW. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology. 2006 Dec;147 (12):5564–7.
  6. Armanini D, Sabbadin C, Donà G, Clari G, Bordin L. Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Expert Opin Pharmacother. 2014 May;15 (7):909–12.
  7. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of pati­ents with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008 Sep;93 (9):3266–81.
  8. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003 Aug;42 (2):161–5.
  9. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002 Jul;40 (1):23–7.
  10. Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension. 2008 Sep;52 (3):529–34.
  11. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005 Apr 19;45 (8):1243–8.
  12. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008 Jan 14;168 (1):80–5.
  13. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin Endocrinol Metab. 2009 Apr;94 (4):1125–30.
  14. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007 Nov;50 (5):911–8.
  15. Catena C, Colussi G, Di Fabio A, Valeri M, Marzano L, Uzzau A, Sechi LA. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res. 2010 Jun;42 (6):440–5.
  16. Steichen O, Lorthioir A, Zinzindohoue F, Plouin PF, Amar L. Outcomes of drug-based and surgical treatments for primary aldosteronism. Adv Chronic Kidney Dis. 2015 May;22 (3):196–203.
  17. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004 Jul 1;351 (1):33–41.
  18. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006 Dec 5;48 (11):2293–300.
  19. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec;40 (6):892–6.
  20. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007 Feb;131 (2):453–9.
  21. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVires C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987 Oct 1;60 (10):820–5.
  22. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003 Apr 2;41 (7):1148–55.
  23. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002 Aug;40 (2):117–23.
  24. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B et al. Effects of eplerenone, enalapril, and eplerenone / enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003 Oct 14;108 (15):1831–8.
  25. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008 Feb;51 (2):432–9.
  26. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24;117 (25):e510–26.
  27. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr;34 (16):1204–14.
  28. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003 May;17 (5):349–52.
  29. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008 Jun 9;168 (11):1159–64.
  30. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010 May;55 (5):1137–42.
  31. Pelliccia F, Rosano G, Patti G, Volterrani M, Greco C, Gaudio C. Efficacy and safety of mineralocorticoid receptors in mild to mode­rate arterial hypertension. Int J Cardiol. 2015 Dec 1;200:8–11.
  32. Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015 Nov;28 (11):1376–85.
  33. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008 Nov-Dec;2 (6):462–8.
  34. Williams B. The principal results of the Prevention and Treatment of Hypertension With Algorithm-based Therapy (PATHWAY) – Optimal treatment of drug resistant hypertension – PATHWAY 2. European Society of Cardiology 2015 Congress. August 31, 2015; London, GB. Abstract 4137.
  35. Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P et al. Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open. 2015 Aug 7;5 (8):e008951.
  36. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001 Dec 6;345 (23):1689–97.
  37. Pitt B. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995 Feb;9 (1):145–9.
  38. Jorde UP, Vittorio T, Katz SD, Colombo PC, Atif F, Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation. 2002 Aug 27;106 (9):1055–7.
  39. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341 (10):709–17.
  40. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000 Nov 28;102 (22):2700–6.
  41. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348 (14):1309–21.
  42. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 Jan 6;364 (1):11–21.
  43. Rogers JK, McMurray JJ, Pocock SJ, Zannad F, Krum H, van Veldhuisen DJ et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012 Nov 6;126 (19):2317–23.
  44. Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011 Nov 1;58 (19):1958–66.
  45. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov;33 (22):2782–95.
  46. Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J. 2011 Jun;161 (6):1024–30.
  47. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013 Feb 27;309 (8):781–91.
  48. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370 (15):1383–92.
  49. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006 Jun 14;295 (22):2638–45.
  50. Epstein M. Aldosterone blockade: an emerging strategy for abroga­ting progressive renal disease. Am J Med. 2006 Nov;119 (11):912–9.
  51. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med. 2010 Jan 7;362 (1):56–65.
  52. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003 May;41 (5):1021–6.
  53. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N et al. Effect of renin-angiotensin- aldosterone system triple blocka­de on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008 Jan;31 (1):59–67.
  54. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldo­sterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009 Mar;4 (3):542–51.
  55. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013 Aug;34 (31):2453–63.
  56. Edwards NC, Steeds R, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol. 2012 Mar;73 (3):447–54.
  57. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int. 2012 May;81 (10):955–68.
  58. Gosse P, Macfadyen RJ. Does eplerenone have a future in the mana­gement of hypertension in Europe? J Hum Hypertens. 2006 Nov;20 (11):829–32.
Гиляревский С. Р., Голшмид М. В., Кузьмина И. М. Блокада минералокортикоидных рецепторов при лечении больных с сердечно-сосудистыми заболеваниями: клинические и фармакологические аспекты применения эплеренона. Сердце: журнал для практикующих врачей. 2016;15 (3):143–150

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En